Table 4 The key reported clinical trials of PD-1/PD-L inhibitors in patients with pancreatic cancer
Tumor type | Target | Drug | Phase and identification | Sample size | Clinical end point | TRAEs | Reference |
|---|---|---|---|---|---|---|---|
PC | PD-L1 | Durvalumab | Phase I/II NCT01693562 | 29 | ORR 7%; 12-week DCR 21% | Any grade (multiple cancer types) 33%, including fatigue, nausea, rash, vomiting, and pyrexia; grade ≥3 (multiple cancer types) 7% | ASCO 2014 [61] |
PC | PD-L1 | MDX1105-01 | Phase I | 14 | ORR 0% | Grades 3–4 (multiple cancer types) 9% | The New England Journal of Medicine [60] |